MCM9 and non-small cell lung carcinoma: To test whether the cancer-specific loss of MCM9 affected HR repair, we compared the ability of NCI-H2291 and NCI-H1299, a control non-small cell lung cancer cell line, to cope with cisplatin-induced DNA damage.